Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025

Barinthus Biotherapeutics plc.

Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.
Cash $112.4M at Dec 31, 2024, down from $142.1M; expected cash runway into 2027.
Revenue $15.0M from Vaxzevria royalties (no future payments expected).
Lead candidate VTP-1000 (celiac disease) Phase 1 AVALON trial; single ascending dose data expected Q3 2025.
VTP-300 for CHB achieved 8 participants with HBsAg loss, 2 functional cures; Phase 2b data due Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.